In The News

Joe Biden is warning that people could lose their health insurance in a U.S. Supreme Court case but an analyst points out the Obama-Biden administration wrecked coverage for millions.

When Senate Democrats grill a Republican Supreme Court nominee, they scathingly predict the nominee will be closed minded and vote along ideological lines. The truth is that only liberal justices do that.

As the November election draws nearer, a key issue will be “Did the Trump tax cuts work?” The answer is an unequivocal “yes.”

Patients and payors can benefit from more affordable treatment in the wake of the pandemic.

What some want to call science is increasingly politics masquerading as science. And nothing has demonstrated that better than the coronavirus. 

Compulsory licensing deters innovators from investing in drug discovery. It won’t reduce what patients pay.

Important legislation has been proposed that would encourage medical and pharmaceutical manufacturing to relocate to the U.S. by providing potent tax incentives instead of threats of government force.

Americans are the world’s top users of generics, but not of biosimilars. State and local governments should encourage a wider uptake for their own employees as an important start—and a much-needed cost savings. 

The job of economic recovery is critical, and the American people are counting on Congress and the Fed to get it done without a political agenda.

Having already entrusted the Fed with hundreds of billions of taxpayer dollars to buy up corporate debt, Congress must insist that the debt purchases be made for exclusively economic reasons.